Insulin Glargine U 300
Brand: Toujeo®
NICE TA:
Indication: Type 1 diabetes mellitus
Disease category: Endocrine system
Commissioning responsibility: CCG
PbR excluded: No
Background
Insulin glargine 300 units/mL (Toujeo®) is recommended as an option in adults with type 1 diabetes mellitus (T1DM) only in accordance with the recommendations in NICE NG17 and in those who experience an unacceptable frequency and/or severity of nocturnal hypoglycaemia on attempting to achieve better glycaemic control during treatment with first-line long-acting insulin analogues; or as a once daily insulin therapy for patients who require assistance with administering injections.
Recommendation
LMMG recommendation: Amber0
Click here to find the definitions for the colour classifications
Reason for decision: Suitable for GP prescribing following recommendation/initiation by specialist
Supporting documents:
LMMG New Medicine Assessment - Insulin Glargine U300 T1DM (315.0 KiB)
Insulin Toujeo Information Sheet And Good Practice Guide (Version 1.1) (255.8 KiB)
Decisions of Lancashire local decision making groups:
| NHS Blackburn With Darwen CCG and NHS East Lancashire CCG | NHS Blackpool CCG | NHS Chorley and South Ribble CCG and NHS Greater Preston CCG | NHS Fylde and Wyre CCG | NHS Morecambe Bay CCG | NHS West Lancashire CCG |
|---|---|---|---|---|---|
Amber0 |
Amber |
Amber0 |
Amber0 |
Amber0 |
Amber0 |
